fluprednisolone has been researched along with Intraocular Pressure in 17 studies
Fluprednisolone: A synthetic glucocorticoid with anti-inflammatory properties.
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data collected from all patients with anterior scleritis who used difluprednate as a single treatment agent from January 1, 2018, to January 1, 2020, including demographics, scleritis type, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, best-corrected visual acuity (BCVA), and lens status." | 8.12 | Effectiveness of Difluprednate for the Treatment of Anterior Scleritis. ( Berkenstock, MK; Burkholder, BM; Liberman, P; Thorne, JE, 2022) |
| " All patients responded well to the cessation of difluprednate and/or use of topical antiglaucomatous agents and no eyes required glaucoma surgery." | 8.12 | Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis. ( Jones, L; Kodati, S; Kumar, A; Sen, HN; Yakin, M, 2022) |
| "To compare intraocular pressure (IOP) outcomes between 2 common, commercially available corticosteroid drops: difluprednate ophthalmic emulsion 0." | 7.85 | Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension. ( Ernest, P; McBain, M; Mian, SI; Musch, DC; Niziol, LM; Person, E; Tijunelis, MA, 2017) |
| "Twenty-seven patients (35 eyes) undergoing treatment with difluprednate 4 times daily for 3 weeks for noninfectious uveitic cystoid macular edema were reviewed for visual acuity, intraocular pressure, optical coherence tomography, and fluorescein angiography results." | 7.85 | RESOLUTION OF NONINFECTIOUS UVEITIC CYSTOID MACULAR EDEMA WITH TOPICAL DIFLUPREDNATE. ( Bena, J; Feiler, DL; Lowder, CY; Pichi, F; Srivastava, SK, 2017) |
| "To evaluate the efficacy and safety of treatment of diabetic macular edema (persistent type) with difluprednate ophthalmic emulsion 0." | 7.83 | Efficacy and safety of topical difluprednate in persistent diabetic macular edema. ( Kaur, S; Sachdev, N; Singh, S; Yangzes, S, 2016) |
| "To identify changes in intraocular pressure (IOP) after vitreoretinal surgical procedures in eyes that received either difluprednate ophthalmic emulsion 0." | 7.80 | Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate. ( Connors, DB; Fine, HF; Jeng, KW; Prenner, JL; Roth, D; Wheatley, HM, 2014) |
| "To evaluate the clinical effect of topical difluprednate in pediatric patients for treatment of noninfectious uveitis." | 7.78 | Efficacy and potential complications of difluprednate use for pediatric uveitis. ( Herlihy, E; Ongchin, S; Slabaugh, MA; van Gelder, RN, 2012) |
| " Safety included evaluation of adverse events." | 6.82 | Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. ( Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016) |
| "In this high-dose pulsed-therapy regimen, difluprednate reduced inflammation more effectively than prednisolone acetate, resulting in more rapid return of vision." | 5.15 | A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. ( Donnenfeld, ED; Fiore, J; Gobbo, A; Holland, EJ; Perry, HD; Prince, J; Sandoval, HP; Shull, ER; Solomon, KD, 2011) |
| "Data collected from all patients with anterior scleritis who used difluprednate as a single treatment agent from January 1, 2018, to January 1, 2020, including demographics, scleritis type, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, best-corrected visual acuity (BCVA), and lens status." | 4.12 | Effectiveness of Difluprednate for the Treatment of Anterior Scleritis. ( Berkenstock, MK; Burkholder, BM; Liberman, P; Thorne, JE, 2022) |
| " All patients responded well to the cessation of difluprednate and/or use of topical antiglaucomatous agents and no eyes required glaucoma surgery." | 4.12 | Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis. ( Jones, L; Kodati, S; Kumar, A; Sen, HN; Yakin, M, 2022) |
| "Patients treated with difluprednate or loteprednol had statistically similar resolution of their AC cell grade and corneal edema at 1 day, 1 week, and 1 month postoperatively (P>0." | 3.88 | Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery. ( Abessi, B; Brooksby, L; Schultze, RL, 2018) |
| "To compare intraocular pressure (IOP) outcomes between 2 common, commercially available corticosteroid drops: difluprednate ophthalmic emulsion 0." | 3.85 | Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension. ( Ernest, P; McBain, M; Mian, SI; Musch, DC; Niziol, LM; Person, E; Tijunelis, MA, 2017) |
| "Twenty-seven patients (35 eyes) undergoing treatment with difluprednate 4 times daily for 3 weeks for noninfectious uveitic cystoid macular edema were reviewed for visual acuity, intraocular pressure, optical coherence tomography, and fluorescein angiography results." | 3.85 | RESOLUTION OF NONINFECTIOUS UVEITIC CYSTOID MACULAR EDEMA WITH TOPICAL DIFLUPREDNATE. ( Bena, J; Feiler, DL; Lowder, CY; Pichi, F; Srivastava, SK, 2017) |
| "To evaluate the efficacy and safety of treatment of diabetic macular edema (persistent type) with difluprednate ophthalmic emulsion 0." | 3.83 | Efficacy and safety of topical difluprednate in persistent diabetic macular edema. ( Kaur, S; Sachdev, N; Singh, S; Yangzes, S, 2016) |
| "To identify changes in intraocular pressure (IOP) after vitreoretinal surgical procedures in eyes that received either difluprednate ophthalmic emulsion 0." | 3.80 | Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate. ( Connors, DB; Fine, HF; Jeng, KW; Prenner, JL; Roth, D; Wheatley, HM, 2014) |
| "To evaluate the clinical effect of topical difluprednate in pediatric patients for treatment of noninfectious uveitis." | 3.78 | Efficacy and potential complications of difluprednate use for pediatric uveitis. ( Herlihy, E; Ongchin, S; Slabaugh, MA; van Gelder, RN, 2012) |
| " Safety included evaluation of adverse events." | 2.82 | Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. ( Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016) |
| " Difluprednate provides effective treatment for anterior uveitis and requires less frequent dosing than prednisolone acetate." | 2.75 | Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. ( Crockett, RS; Davanzo, R; Flynn, TE; Foster, CS; McLeod, K; Vogel, R, 2010) |
| " In this regard, the present study was conducted with the aim of studying the efficacy of using fixed drug combination (Difluprednate and Moxifloxacin) in reducing ocular inflammation and pain in post-operative patients undergoing cataract surgery." | 1.46 | Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India. ( Anuradha, A; Nishath, S; Rashmi, G; Shilpa, R; Vidyadevi, M, 2017) |
| "Current treatment of glaucoma relies on administration of daily drops or eye surgery." | 1.43 | Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy. ( Borrás, T; Buie, LK; Spiga, MG, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Liberman, P | 1 |
| Burkholder, BM | 1 |
| Thorne, JE | 1 |
| Berkenstock, MK | 1 |
| Yakin, M | 1 |
| Kumar, A | 1 |
| Kodati, S | 1 |
| Jones, L | 1 |
| Sen, HN | 1 |
| Tijunelis, MA | 1 |
| Person, E | 1 |
| Niziol, LM | 1 |
| Musch, DC | 1 |
| Ernest, P | 1 |
| McBain, M | 1 |
| Mian, SI | 1 |
| Abessi, B | 1 |
| Brooksby, L | 1 |
| Schultze, RL | 1 |
| Vidyadevi, M | 1 |
| Anuradha, A | 1 |
| Rashmi, G | 1 |
| Shilpa, R | 1 |
| Nishath, S | 1 |
| Kakimoto, H | 1 |
| Takamura, Y | 1 |
| Arimura, S | 1 |
| Miyake, S | 1 |
| Matsumura, T | 1 |
| Gozawa, M | 1 |
| Iwasaki, K | 1 |
| Morioka, M | 1 |
| Yamada, Y | 1 |
| Inatani, M | 1 |
| Sheppard, JD | 1 |
| Toyos, MM | 1 |
| Kempen, JH | 1 |
| Kaur, P | 1 |
| Foster, CS | 2 |
| Jeng, KW | 1 |
| Fine, HF | 1 |
| Wheatley, HM | 1 |
| Roth, D | 1 |
| Connors, DB | 1 |
| Prenner, JL | 1 |
| Kaur, S | 1 |
| Yangzes, S | 1 |
| Singh, S | 1 |
| Sachdev, N | 1 |
| Borrás, T | 1 |
| Buie, LK | 1 |
| Spiga, MG | 1 |
| Wilson, ME | 1 |
| O'Halloran, H | 1 |
| VanderVeen, D | 1 |
| Roarty, J | 1 |
| Plager, DA | 1 |
| Markwardt, K | 1 |
| Gedif, K | 1 |
| Lambert, SR | 1 |
| Feiler, DL | 1 |
| Srivastava, SK | 1 |
| Pichi, F | 1 |
| Bena, J | 1 |
| Lowder, CY | 1 |
| Davanzo, R | 1 |
| Flynn, TE | 1 |
| McLeod, K | 1 |
| Vogel, R | 1 |
| Crockett, RS | 1 |
| Birnbaum, AD | 1 |
| Jiang, Y | 1 |
| Tessler, HH | 1 |
| Goldstein, DA | 1 |
| Donnenfeld, ED | 1 |
| Holland, EJ | 1 |
| Solomon, KD | 1 |
| Fiore, J | 1 |
| Gobbo, A | 1 |
| Prince, J | 1 |
| Sandoval, HP | 1 |
| Shull, ER | 1 |
| Perry, HD | 1 |
| Slabaugh, MA | 1 |
| Herlihy, E | 1 |
| Ongchin, S | 1 |
| van Gelder, RN | 1 |
| Bradshaw, SE | 1 |
| Shankar, P | 1 |
| Maini, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis[NCT01201798] | Phase 3 | 111 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [NCT00501579] | Phase 3 | 0 participants | Interventional | Completed | |||
| A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal [NCT01244334] | Phase 4 | 52 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Lack of efficacy was defined as those subjects who discontinued study participation either due to treatment failure or an adverse event with a preferred term of iridocyclitis, iritis, uveitis, or vitritis. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Time to Event
| Intervention | Percentage of subjects (Number) |
|---|---|
| Durezol | 0 |
| Pred Forte | 14.9 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = ≤ 1 cell count; 1 = 2 to 10 cell count; 2 = 11 to 20 cell count; 3 = 21 to 50 cell count; and 4 = > 50 cell count. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 21, Day 28, Day 35, Day 42
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (Day 0) | Day 3 | Day 7 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 2.6 | -1.1 | -1.8 | -2.4 | -2.3 | -2.3 | -2.3 |
| Pred Forte | 2.6 | -1.0 | -1.6 | -2.1 | -2.1 | -2.1 | -2.1 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = ≤ 1 cell count; 1 = 2 to 10 cell count; 2 = 11 to 20 cell count; 3 = 21 to 50 cell count; and 4 = > 50 cell count. (NCT01201798)
Timeframe: Baseline (Day 0), Day 14
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline (Day 0) | Day 14 | |
| Durezol | 2.6 | -2.2 |
| Pred Forte | 2.6 | -2.0 |
Anterior chamber flare (protein escaping from dialated vessels) was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (Day 0) | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 2.2 | -1.1 | -1.6 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
| Pred Forte | 2.3 | -1.2 | -1.6 | -1.9 | -2.0 | -2.0 | -2.0 | -2.0 |
The following signs were each graded on a 0 - 3 scale (0 = absent; 1 = mild; 2 = moderate; 3 = severe): posterior synechia, hypopyon, limbal injection, and keratic precipitates. Peripheral synechia was graded by the combined number of clock hours affected (0 = absent; 1 = < 3 hrs; 2 = 3-6 hours; 3 = > 6 hours). The total sign score was calculated as the sum of the 5 individual sign scores, the anterior chamber cell grade and the anterior chamber flare grade. The minimum/best total sign score was 0, and the maximum/worst total sign score was 23. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (Day 0) | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 7.1 | -3.5 | -5.2 | -6.1 | -6.5 | -6.4 | -6.3 | -6.2 |
| Pred Forte | 7.3 | -3.6 | -5.0 | -5.8 | -6.2 | -6.2 | -6.2 | -6.3 |
The following symptoms were each graded by the subject according to a 0-100 visual analog scale (VAS) using a mark on a 100 mm line (0 = absent, 100 = maximal): eye pain, photophobia, blurred vision, and lacrimation. The total symptom score was calculated as the sum of the 4 individual symptom scores. (NCT01201798)
Timeframe: Baseline (Day 0), Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (Day 0) | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 186.7 | -88.4 | -108.2 | -133.3 | -138.8 | -140.1 | -143.9 | -146.2 |
| Pred Forte | 203.2 | -88.4 | -123.8 | -137.4 | -149.5 | -152.4 | -147.3 | -155.5 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and recorded based on actual cell count. Anterior chamber flare (protein escaping from dialated vessels) was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Percentage of subjects (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 13.0 | 41.3 | 78.3 | 82.6 | 80.4 | 82.6 | 80.4 |
| Pred Forte | 14.9 | 40.4 | 61.7 | 76.6 | 76.6 | 76.6 | 78.7 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and recorded based on actual cell count. Proportion is reported as a percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Percentage of subjects (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 13.0 | 21.7 | 52.2 | 73.9 | 73.9 | 69.6 | 69.6 |
| Pred Forte | 2.1 | 21.3 | 38.3 | 48.9 | 63.8 | 63.8 | 68.1 |
As assessed by the investigator during slit lamp examination. Anterior chamber cell grade was graded on a 5-point scale, with 0 = no cells; 1 = 1 to 10 cells; 2 = 11 to 20 cells; 3 = 21 to 50 cells; and 4 = more than 50 cells. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Percentage of subjects (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 50.0 | 87.0 | 93.5 | 93.5 | 93.5 | 93.5 | 91.3 |
| Pred Forte | 57.4 | 80.9 | 85.1 | 89.4 | 87.2 | 85.1 | 85.1 |
Inflammatory cells in the anterior chamber were assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = ≤ 1 cell count; 1 = 2 to 10 cell count; 2 = 11 to 20 cell count; 3 = 21 to 50 cell count; and 4 = > 50 cell count. Proportion is reported as percentage of subjects. (NCT01201798)
Timeframe: Day 3, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42
| Intervention | Percentage of subjects (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 | |
| Durezol | 15.2 | 34.8 | 65.2 | 84.8 | 80.4 | 78.3 | 76.1 |
| Pred Forte | 6.4 | 25.5 | 55.3 | 63.8 | 70.2 | 70.2 | 74.5 |
4 trials available for fluprednisolone and Intraocular Pressure
| Article | Year |
|---|---|
Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anterior Chamber; Anti-Inflammator | 2014 |
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Administration, Topical; Aphakia, Postcataract; Cataract; Cataract Extraction; Child, Preschool; Dou | 2016 |
Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis.
Topics: Adult; Anterior Chamber; Anti-Inflammatory Agents; Emulsions; Female; Fluprednisolone; Glucocorticoi | 2010 |
A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery.
Topics: Aged; Aged, 80 and over; Cell Count; Cornea; Corneal Edema; Double-Blind Method; Endothelium, Cornea | 2011 |
13 other studies available for fluprednisolone and Intraocular Pressure
| Article | Year |
|---|---|
Effectiveness of Difluprednate for the Treatment of Anterior Scleritis.
Topics: Adolescent; Adult; Aged; Female; Fluprednisolone; Glucocorticoids; Humans; Intraocular Pressure; Mid | 2022 |
Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.
Topics: Child; Fluprednisolone; Glaucoma; Glucocorticoids; Humans; Intraocular Pressure; Retrospective Studi | 2022 |
Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension.
Topics: Cataract Extraction; Fluprednisolone; Glucocorticoids; Humans; Incidence; Intraocular Pressure; Ocul | 2017 |
Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery.
Topics: Aged; Aged, 80 and over; Anterior Chamber; Anti-Inflammatory Agents; Cataract Extraction; Cornea; Co | 2018 |
Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India.
Topics: Anti-Bacterial Agents; Cataract Extraction; Dose-Response Relationship, Drug; Drug Combinations; End | 2017 |
Effect of 0.05% Difluprednate Ophthalmic Emulsion on Proinflammatory Cytokine Levels After Retinal Laser Photocoagulation in Rabbits.
Topics: Animals; Aqueous Humor; Cytokines; Emulsions; Fluprednisolone; Intraocular Pressure; Laser Coagulati | 2018 |
Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate.
Topics: Emulsions; Female; Fluprednisolone; Glucocorticoids; Humans; Incidence; Intraocular Pressure; Male; | 2014 |
Efficacy and safety of topical difluprednate in persistent diabetic macular edema.
Topics: Aged; Diabetic Retinopathy; Female; Fluprednisolone; Follow-Up Studies; Glucocorticoids; Humans; Int | 2016 |
Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy.
Topics: Animals; Dependovirus; Disease Models, Animal; Fluprednisolone; Genetic Therapy; Genetic Vectors; Gl | 2016 |
RESOLUTION OF NONINFECTIOUS UVEITIC CYSTOID MACULAR EDEMA WITH TOPICAL DIFLUPREDNATE.
Topics: Administration, Topical; Adult; Aged; Female; Fluorescein Angiography; Fluprednisolone; Glucocortico | 2017 |
Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate.
Topics: Administration, Topical; Adolescent; Adult; Child; Fluprednisolone; Glucocorticoids; Humans; Intraoc | 2011 |
Efficacy and potential complications of difluprednate use for pediatric uveitis.
Topics: Administration, Topical; Adolescent; Aqueous Humor; Cataract; Child; Female; Fluprednisolone; Glucoc | 2012 |
Topical steroid and antibiotic combination therapy in red eye conditions.
Topics: Anti-Inflammatory Agents; Betamethasone; Contraindications; Drug Combinations; Eye Diseases; Flupred | 2006 |